Yes, thanks, Mark. Let’s focus first on our adjusted operating income which has been compounding over the years. I think in 2015, we had about 4 million, 5 million in operating income; 2016, it was about 15 million. This year it’s tracking to 21 million, 22 million. And then in '18, '19 and '20, it will probably go up to like $30 million, $40 million, $50 million as the years go on. What we have been doing at the core of our business is spending about $15 million to acquire approximately 100,000 pets and that has been relatively consistent for the last couple of years. And in this year, which we didn’t have the room last year, we’re going to be doing – spending a couple of million dollars in testing to find out if we can pull some levers to help to cost effectively accelerate growth in future years, as our adjusted operating income becomes larger and larger, we then need to invest it with strong internal rates of returns or have that money go into EBITDA or pay dividends back to our shareholders. So with the size and penetration rate of the market, we want to be able to grow consistently 20% to 30% year-over-year. And the testing that we’re going to be doing is regional test, kind of TV, radio-type testing. When we test it out, it might have an LVP to PAC ratio of maybe 1 to 1 or 1 to 2, but we’ll want it to get to a place where it has an internal rate of return of a longer term target of maybe 40% for us to start to deploy bigger amounts of that capital. So I would think for the balance of this year and probably for 2018, we’ll be spending more money testing. And as we become effective at it, then we can use that to help accelerate growth in the outer years as we have more free cash flow to do so. But last year, as a reminder, we had about 15 million in adjusted operating income and we spent about 15 million acquiring pets. That kind of got us to cash flow breakeven. This year, we’re tracking for about 22 million adjusted operating income and maybe we’ll spend 15 million on core and 2 million to 3 million on tests will give ourselves a little bit of EBITDA, unless some of these tests become fruitful and then we can start to kind of pull those levers.